Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Proposal for a predictive model of erectile function after permanent 125I prostate brachytherapy for localized prostate cancer

International Journal of Impotence Research volume 25, pages 121–126 (2013)Cite this article

Subjects

Abstract

To determine the risk factors for EDin men treated by prostate brachytherapy (PB) for localized prostate cancer and to propose a model to predict post-implant erectile function. Out of a series of 270 sexually active men treated by PB, 241 (89%) (mean age=66 years (range, 43–80)) accepted to participate in a mail-based study on erectile function. The risk factors for erectile dysfunction were determined by regression analysis and a predictive model was proposed. The performance of the model was determined in this population and subsequently verified in a population of 50 men treated by PB in another treatment center. The risk factors for ED after PB were age, the pre-implant IIEF score and prostate volume. In the studied population, the final model to predict a post-treatment IIEF-5 score, using these factors, had a sensitivity of 69% and a specificity of 68% associated to an area under the ROC curve (AUC) of 0.75. The same performance was obtained in another treatment center. Age, pre-implant IIEF-5 score and prostate volume may be used to predict post-implant erectile function in patients treated by PB.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Colonna M, Danzon A, Delafosse P, Mitton N, Bara S, Bouvier AM et al. Cancer prevalence in France: time trend, situation in 2002 and extrapolation in 2012. Eur J Cancer 2008; 44: 115–122.

    Article  Google Scholar 

  2. Jemal A, Sigel R, Ward E, Murray T, Xu J, Thun MJ . Cancer statistics 2007. CA Cancer J Clin 2007; 57: 43–66.

    Article  Google Scholar 

  3. Bokhour BG, Clark JA, Inui TS, Silliman RA, Talcott JA . Sexuality after treatment for early prostate cancer: exploring the meanings of ‘erectile dysfunction’. J Gen Intern Med 2001; 16: 649–655.

    Article  CAS  Google Scholar 

  4. Robinson JW, Moritz S, Fung T . Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 1063–1068.

    Article  Google Scholar 

  5. Nag S, Ellis RJ, Merrick GS, Bahnson R, Wallner K, Stock R et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54: 462–470.

    Article  Google Scholar 

  6. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  Google Scholar 

  7. Cappelleri JC, Rosen RC . The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005; 17: 307–319.

    Article  CAS  Google Scholar 

  8. Delaunay B, Delannes M, Salloum A, Delavierre D, Wagner F, Jonca F et al. Orgasm after prostate curietherapy with Iode 125 permanent implants for localized cancer of the prostate. Prog Urol 2011; 21: 932–939.

    Article  CAS  Google Scholar 

  9. Schiff JD, Bar-Chama N, Cesaretti J, Stock R . Early use of phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int 2006; 98: 1255–1558.

    Article  CAS  Google Scholar 

  10. Huyghe E, Delannes M, Wagner F, Delaunay B, Nohra J, Thoulouzan M et al. Ejaculatory function after permanent 125I prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 126–132.

    Article  Google Scholar 

  11. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306: 1205–1214.

    Article  CAS  Google Scholar 

  12. MacDonald AG, Keyes M, Kruk A, Duncan G, Moravan V, Morris WJ . Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important? Clin invest 2005; 63: 155–163.

    Google Scholar 

  13. Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM et al. A population based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108–113.

    Article  Google Scholar 

  14. Miller DC, Wei JT, Down RL, Montie JE, Pimentel H, Sandler HM et al. Use medications or devices for erectile dysfunction among long-term prostate cancer treatments survivors: potential influence of sexual motivation and/or indifference. Adult Urol 2006; 68: 166–171.

    Article  Google Scholar 

  15. Stock RG, Kao J, Stone NN . Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165: 436–439.

    Article  CAS  Google Scholar 

  16. Merrick GS, Butler WM, Wallner KE, Lief JH, Anderson RL, Smeiles BJ et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002; 54: 1055–1062.

    Article  Google Scholar 

  17. McLaughlin PW, Narayana V, Drake DG, Miller BM, Marsh L, Chan J et al. Comparison of MRI pulse sequences in defining prostate volume after permanent implantation. Int J Radiat Oncol Biol Phys 2002; 54: 703–711.

    Article  CAS  Google Scholar 

  18. Solan AN, Cesaretti JA, Stone NN, Stock RG . There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 73: 1468–1474.

    Article  Google Scholar 

  19. Gillan CG, Kirilova A, Landon A, Yeung I, Pond G, Crook J . Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. Int J Oncol Biol Phy 2006; 65: 688–693.

    Article  Google Scholar 

  20. Valdani R, Rancati T, Fiorino C . Predictive models of toxicity with external radiotherapy for prostate Cancer. Cancer 2009; 115: 3141–3145.

    Article  Google Scholar 

  21. Van Der Wielen GJ, Van Putten WI, Incrocci L . Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 2007; 68: 479–484.

    Article  Google Scholar 

  22. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A et al. Long term, tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85: 2460–2468.

    Article  CAS  Google Scholar 

  23. Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A et al. Percent free prostate specific antigen is an accurate predictor of prostate Cancer risk in men with serum PSA 2.5ng/ml and lower. Cancer 2008; 113: 2695–2703.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Nina Crowte and John Woodley for the English translation. The work was supported by the Ligue Nationale contre le Cancer, France.

Author information

Authors and Affiliations

  1. Department of Urology and Andrology, University Hospital, CHU Rangueil, Toulouse, France

    E Huyghe, B Delaunay & M Soulie

  2. Department of Urology and Andrology, EA 3694, Paul Sabatier University, CHU Paule de Viguier, Toulouse, France

    E Huyghe, P Njomnang Soh & M Walschaerts

  3. Department of Radiotherapy, Claudius Regaud Cancer Center, Toulouse, France

    M Delannes & J M Bachaud

  4. Department of Urology, Orleans University Hospital, Orleans, France

    D Delavierre

Authors
  1. E Huyghe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Delaunay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Njomnang Soh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Delannes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Walschaerts
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Delavierre
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Soulie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J M Bachaud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Huyghe.

Ethics declarations

Competing interests

The authors declare no confict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huyghe, E., Delaunay, B., Njomnang Soh, P. et al. Proposal for a predictive model of erectile function after permanent 125I prostate brachytherapy for localized prostate cancer. Int J Impot Res 25, 121–126 (2013). https://doi.org/10.1038/ijir.2013.3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2013.3

Keywords

Search

Advanced search

Quick links